Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model

Brain Research

Volumn 1591, Issue 1, 2014, Pages 111-117

  Lieu, Christopher A ^a   Dewey, Colleen M ^a   Chinta, Shankar J ^a   Rane, Anand ^a   Rajagopalan, Subramanian ^a   Batir, Sean ^a   Kim, Yong Hwan ^a   Andersen, Julie K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Astrocyte; Behavior; Lithium; Neuroinflammation; Parkinson's disease; Striatum

Indexed keywords

LITHIUM; PARKIN; TYROSINE 3 MONOOXYGENASE; DOPAMINE; NEUROPROTECTIVE AGENT;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; EXPLORATORY BEHAVIOR TEST; LOW DRUG DOSE; MOUSE; MOUSE MUTANT; NONHUMAN; OPEN FIELD TEST; PARKINSONISM; PHENOTYPE; POLE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REARING; TRANSGENIC MOUSE; AGING; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG EFFECTS; GENETICS; MOTOR ACTIVITY; NEOSTRIATUM; PARKINSON DISEASE; SUBSTANTIA NIGRA;

ANIMALIA; MUS MUSCULUS; PARKINSONIA;

AGING; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; LITHIUM; MICE, TRANSGENIC; MOTOR ACTIVITY; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84922567318     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2014.10.032     Document Type: Article

References (32)

1. Arraf, Z., et al., 2012. Lithium and oxidative stress lessons from the MPTP model of Parkinson's disease. Neurosci. Lett. 516,57-61.
2. Baker, K.A., et al., 2000. Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease. Exp. Neurol. 162, 350-360.
3. Beraud, D., et al., 2013. Microglial activation and antioxidant responses induced by the Parkinson's disease protein alphasynuclein. J. Neuroimmune Pharmacol 8, 94-117.
4. Brandish, P.E., et al., 2005. Regulation of gene expression by lithium and depletion of inositol in slices of adult rat cortex. Neuron. 45, 861-872.
5. Cerbai, F., et al., 2012. The neuron-astrocyte-microglia triad in normal brain ageing and in a model of neuroinflammation in the rat hippocampus. PLoS One 7, e45250.
6. Fleming, S.M., et al., 2004. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alphasynuclein. J. Neurosci. 24, 9434-9440.
7. Frank-Cannon, T.C., et al., 2008. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J. Neurosci. 28, 10825-10834.
8. Hernandez, L.F., et al., 2013. Selective effects of dopamine depletion and L-DOPA therapy on learning-related firing dynamics of striatal neurons. J. Neurosci. 33, 4782-4795.
9. Kang, K., et al., 2012. Lithium pretreatment reduces brain injury after intracerebral hemorrhage in rats. Neurol. Res. 34,447-454.
10. Kaushik, D.K., Basu, A., 2013. A friend in need may not be a friend indeed: role of microglia in neurodegenerative diseases. CNS Neurol. Disord. Drug Targets 12, 726-740.
11. Kim, Y.H., et al., 2011. Lithium protects against oxidative stressmediated cell death in alpha-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease. J. Neurosci. Res. 89, 1666-1675.
12. King, T.D., Bijur, G.N., Jope, R.S., 2001. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res. 919, 106-114.
13. Li, X.Z., et al., 2013. Therapeutic effects of valproate combined with lithium carbonate on MPTP-induced parkinsonism in mice: possible mediation through enhanced autophagy. Int. J. Neurosci. 123, 73-79.
14. Lieu, C.A., et al., 2013. Age-related behavioral phenotype of an astrocytic monoamine oxidase-B transgenic mouse model of Parkinson's disease. PLoS One 8, e54200.
15. Lu, X.H., et al., 2009. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit agedependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J. Neurosci. 29, 1962-1976.
16. Malhi, G.S., et al., 2013. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs 27, 135-153.
17. Mallajosyula, J.K., et al., 2008. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One 3, e1616.
18. Munoz-Montano, J.R., et al., 1997. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411, 183-188.
19. Mythri, R.B., et al., 2011. Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem. Res. 36, 1452-1463.
20. Nahman, S., Belmaker, R.H., Azab, A.N., 2012. Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells. Innate Immun. 18, 447-458.
21. Peng, J., et al., 2009. Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation. Free Radical Biol. Med.46, 312-320.
22. Reeve, A., Simcox, E., Turnbull, D., 2014. Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res. Rev 14C, 19-30.
23. Richardson, J.R., Hossain, M.M., 2013. Microglial ion channels as potential targets for neuroprotection in Parkinson's disease. Neural Plast. 2013, 587418.
24. Shen, H.C., Li, J.Y., Lo, Y.K., 2007. Lithium intoxication-induced acute parkinsonism complicated with hyperparathyroidism and nephrogenic diabetes insipidus: report of a case. Acta Neurol. Taiwan. 16, 231-233.
25. Smith, Y., et al., 2012. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 37, 213-246.
26. Stott, S.R., Barker, R.A., 2014. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease. Eur. J. Neurosci. 39, 1042-1056.
27. Su, W., et al., 2012. Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients. Clin. Neurol. Neurosurg. 114,372-375.
28. Su, Y., et al., 2004. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43, 6899-6908.
29. Wang, H.M., et al., 2013. Inhibition of glycogen synthase kinase- 3beta by lithium chloride suppresses 6-hydroxydopamineinduced inflammatory response in primary cultured astrocytes. Neurochem. Int. 63, 345-353.
30. Wei, H., et al., 2001. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106, 603-612.
31. Youdim, M.B., Arraf, Z., 2004. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl- 2 and Bax. Neuropharmacology 46, 1130-1140.
32. Willing, A.E., et al., 2002. Lithium exposure enhances survival of NT2N cells (hNT neurons) in the hemiparkinsonian rat. Eur. J. Neurosci 16 (12), 2271-2278.